Luxturna Carries Potential to Correct Blindness, $850k Price Tag
Spark Therapeutics CEO Jeff Marrazzo reassured patients and the medical community he has an obligation to ensure access to the novel gene therapy.
Unapproved Stem Cell Therapies Are Causing "Dismal" Health Outcomes
Companies are skirting regulation to be the first to build the next big stem cell therapy, creating clinical concerns and poor patient outcomes.
FDA Accepts Application for Potential First Gene Therapy for Genetic Disease in US
If approved, LUXTURNA would also be the first pharmacological treatment for inherited retinal disease